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Infantile cortical hyperostosis (Caffey disease) is characterized by spontaneous episodes of subperiosteal new 
bone formation along 1 or more bones commencing within the first 5 months of life. A genome-wide screen 
for genetic linkage in a large family with an autosomal dominant form of Caffey disease (ADC) revealed a locus 
on chromosome 17q21 (LOD score, 6.78). Affected individuals and obligate carriers were heterozygous for a 
missense mutation (3040C→T) in exon 41 of the gene encoding the α1(I) chain of type I collagen (COL1A1), 
altering residue 836 (R836C) in the triple-helical domain of this chain. The same mutation was identified 
in affected members of 2 unrelated, smaller families with ADC, but not in 2 prenatal cases and not in more 
than 300 chromosomes from healthy individuals. Fibroblast cultures from an affected individual produced 
abnormal disulfide-bonded dimeric α1(I) chains. Dermal collagen fibrils of the same individual were larger, 
more variable in shape and size, and less densely packed than those in control samples. Individuals bearing 
the mutation, whether they had experienced an episode of cortical hyperostosis or not, had joint hyperlaxity, 
hyperextensible skin, and inguinal hernias resembling symptoms of a mild form of Ehlers-Danlos syndrome 
type III. These findings extend the spectrum of COL1A1-related diseases to include a hyperostotic disorder.
Introduction
Infantile cortical hyperostosis (Caffey disease; OMIM 114000) is 
a genetic disorder characterized by an infantile episode of massive 
subperiosteal new bone formation that typically involves the diaphy-
ses of the long bones, mandible, and clavicles (1). In addition to these 
changes, which can appear quite prominently on x-ray, the involved 
bones may also appear inflamed, with painful swelling and systemic 
fever often accompanying the illness. Consistent with the observed 
increased bone formation, laboratory findings include an elevated 
level of alkaline phosphatase. Furthermore, there can be an eleva-
tion in white blood cell count and erythrocyte sedimentation rate, 
which indicate an inflammatory response. The bone changes usually 
begin before 5 months of age and resolve before 2 years of age (1, 2). 
Recurrent episodes of cortical hyperostosis are uncommon, and 
there are few reports concerning adverse sequelae of the hyperos-
totic lesions in affected individuals (3, 4). The inflammatory nature 
of the symptoms has led to treatment trials with antiinflammatory 
agents, and resolution of symptoms has been reported with the use 
of indomethacin (5) and with glucocorticoid therapy (6).
Information on several unrelated pedigrees indicates that 
Caffey disease can be inherited in an autosomal dominant man-
ner (7–9). Review of these pedigrees showed evidence of incom-
plete penetrance, as there were obligate carriers who lacked 
episodes of cortical hyperostosis (7–9). However, the signs and 
symptoms of Caffey disease can be subtle and are typically only 
manifested at a preverbal age, which thus makes it plausible 
that the diagnosis could have been missed in some of these 
apparently unaffected carriers. A more severe and often lethal 
prenatal form of Caffey disease appears to be inherited as an 
autosomal recessive disorder (10).
In addition to the inherited forms of Caffey disease, sporadic 
cases of infantile cortical hyperostosis have also been described 
(reviewed in ref. 11). At least some of these nonfamilial cases can 
be attributed to administration of prostaglandin E1 (PGE1) and 
PGE2 for treatment of ductal-dependent cardiac lesions (12–14). 
In fact, the incidence of this complication of prostaglandin 
therapy is high, with radiographic changes occurring in 62% of 
all infants receiving PGE1 infusion for more than 60 days (14). 
Other conditions that can cause cortical bone lesions in children 
less than 2 years of age, and may thus mimic infantile cortical 
hyperostosis, include trauma (15), hypervitaminosis A (16), hyper-
phosphatemia (17), and infection (18). Sporadic cases of infantile 
cortical hyperostosis not associated with PGE1 or PGE2 infusion 
appear to be on the decline, but the reason(s) for the diminished 
frequency of these bone abnormalities remain(s) uncertain (8).
Nonstandard abbreviations used: ADC, autosomal dominant form of Caffey 
disease; COL1A1, gene encoding the α1(I) chain of type I collagen; CB6, cyanogen bro-
mide peptide 6; PGE1, prostaglandin E1.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 115:1250–1257 (2005).  
doi:10.1172/JCI200522760.
  Related Commentary, page 1142
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 115   Number 5   May 2005 1251
The gene or genes responsible for the prenatal and postnatal 
inherited forms of Caffey disease have not been reported. We there-
fore undertook genetic linkage studies using genomic DNA from 
a large kindred with the autosomal dominant form of the condi-
tion (autosomal dominant Caffey disease [ADC]) (7, 8). Affected 
individuals and obligate carriers in this kindred, as well as affected 
individuals in 2 other kindreds, were shown to be heterozygous for 
the same novel missense mutation affecting the gene that encodes 
the α1(I) chain of type I collagen (COL1A1).
Results
Genetic linkage analysis. Three unrelated families with at least 2 
members affected by ADC (7, 8, 19) (Figure 1), 1 sporadic case, 
and 2 prenatal cases were available for analysis (20, 21). DNA 
from family 1 was used for a genome-wide scan, which revealed 
linkage to chromosome 17q21 (Figure 2A). Fine mapping 
reduced the size of the linked region to a 2.3-Mb interval delim-
ited by markers D17S1868 and D17S1877. The maximal LOD 
score obtained within this region by 2-point analysis was 6.78 
for marker D17S1795 (θ = 0), which is only slightly lower than 
the maximal theoretical LOD score of 7.12. Nucleotide sequence 
analysis of 13 candidate genes within the linked region (GNGT2, 
NESH, PHB, LOC81558, ITGA3, LOC84687, XT2, PRO1855, 
CHAD, EPN3, FLJ21347, OA48-18, and TOB1) did not reveal any 
heterozygous mutations that segregated with ADC. However, 
affected individuals and obligate carriers were heterozygous 
for a missense mutation in exon 41 of COL1A1 (also referred 
to as exon 42, corresponding to the exon structure of COL1A2, 
which contains 1 additional exon; ref. 22) (Figure 3). This C→T 
transition at nucleotide position 3040 of the cDNA (relative to 
the translation initiation codon), which alters codon 1014 of 
prepro-α1(I) mRNA, was predicted to produce an R836C amino 
acid substitution within the triple-helical domain of the α1(I) 
chain of collagen. The nucleotides were numbered relative to the 
ATG start site of prepro-α1(I) cDNA, and amino acid residues 
were numbered relative to the first glycine residue of the main 
triple-helical domain of the α1(I) protein chain (22).
To confirm the mutation identified by sequence analysis, a 
495-bp fragment comprising exon 41 was PCR amplified and 
digested with HpyCH4IV (ACGT). The PCR product derived from 
the mutant allele lacked 1 recognition site for HpyCH4IV, thus 
generating an additional DNA fragment of 319 bp (Figure 2B). 
The same COL1A1 mutation was also found in the 3 affected 
members but not in the unaffected father of family 2 (Figure 2C). 
Furthermore, the mutation was found in the clinically affected 
identical twins but not in the clinically unaffected parents and 
brother of family 3 (Figure 2D). The affected twins and the unaf-
fected sibling had inherited identical parental alleles in this 
region. Consequently, the clinically affected twins were likely to 
have acquired a de novo COL1A1 mutation.
Haplotype analysis of the affected members of families 1–3 did 
not reveal any shared alleles, which supported the historical evi-
dence that the 3 families that were heterozygous for the R836C 
substitution were not related to each other. The 3040C→T 
transition was not detected in genomic DNA from more than 150 
healthy controls (more than 300 chromosomes), in SNP databas-
es (dbSNP, http://www.ncbi.nlm.nih.gov/SNP; JSNP, http://snp.
ims.u-tokyo.ac.jp; Celera Discovery System, http://publication. 
celera.com/humanpub/index.jsp; and Applied Biosystems 
SNPbrowser Software, http://marketing.appliedbiosystems.
com/mk/get/snpb_landing), or in the Mutations in COL1A1 
database (http://www.le.ac.uk/genetics/collagen/col1a1.html) 
(22). The latter findings suggest that the 3040C→T transition 
in exon 41 of COL1A1 and the resulting R836C amino acid sub-
stitution within the triple-helical domain of the α1(I) chain can 
be a cause of ADC.
A possible sporadic case of Caffey disease with hyperostosis of a 
rib did not have any demonstrable mutations in COL1A1 or in the 
COL1A2 gene, which encodes the α2(I) chain of type I collagen. 
Mutations of COL1A1 or COL1A2 were also not detected in 2 cases 
of prenatal Caffey disease (20, 21).
Dermal collagen morphology and collagen biosynthesis. To further 
investigate whether the Col1A1 mutation results in changes in 
type I collagen, we obtained skin biopsies from an affected adult 
female in family 1 (IV-2). This individual had an episode of infan-
tile cortical hyperostosis and from early childhood had clinical 
signs of hyperextensible skin and generalized joint instability, as 
well as a history of several fractures. As an adult, she had the 
same clinical signs, as well as more severe voluntary subluxation 
of the shoulders. Electron microscopy of her dermis showed 
normal fibroblast morphology (data not shown). The collagen 
fibrils were more variable in shape and size and were less densely 
Figure 1
Radiographic features of infantile cortical hyperostosis. Radiographs 
of 3 affected individuals of 2 unrelated kindreds showing subperiosteal 
thickening of the femur, tibia, and fibula (left and upper middle panels: 
tibia and fibula, respectively, of twin II-1 of family 3; upper right panel: 
fibula of patient II-1 of family 2), and metacarpals of the left foot (lower 
right panel: twin II-2 of family 3). Note that the periosteum, which is 
normally anchored at the growth plates where it is continuous with 
the perichondrium, was frequently elevated circumferentially from the 
proximal to the distal growth plates (open arrows). The bone marrow 
cavities were also narrowed (filled arrows).
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packed (Figure 4A) than fibrils in age- and sex-matched control 
dermal samples (Figure 4B). The fibrils were also significantly 
larger and were more variable in size in the affected individu-
al (Caffey disease, 108 ± 15 nm; control, 91 ± 8 nm; n = 1,000; 
P < 0.001). Granular material was visible in the matrix surround-
ing many of the collagen fibrils (Figure 4A).
One-dimensional gel electrophoresis showed that cultured der-
mal fibroblasts from the proband of family 1 produced a mix-
ture of apparently normal type I, III, and V collagens as well as 
an abnormal disulfide-linked dimer (Figure 5A). As the dimer 
was likely to include 2 α1(I) chains bearing the R836C substitu-
tion, it was designated β11′. Two-dimensional gel electrophoresis 
showed that the abnormal β11′ dimers dissociated after reduc-
tion of disulfide bonds into α1(I) chains that were designated 
as α1(I)′ chains (Figure 5B). Although β-aminopropionitrile, 
an inhibitor of the formation of lysine-derived collagen cross-
linkages, was added to the cultures, a small amount of dimeric 
collagen chains (β11 and β12) was formed. These lysine-derived 
crosslinked dimers do not dissociate into α chains after reduc-
tion of disulfide bonds with dithiothreitol.
Genotype/phenotype correlations. Of the 24 members of family 1 in 
our study with the R836C mutation, only 19 members had expe-
rienced an episode of cortical hyperostosis, while 5 were obligate 
carriers. Thus, 79% of the individuals who were heterozygous for 
the COL1A1 mutation had an episode of cortical hyperostosis, 
and 21% of them did not. Detailed interviews of family members 
did not reveal any precipitating events other than the consistent 
report that the onset of cortical hyperostosis usually occurred 
before 5 months of age. None of the children had been given pros-
taglandins, which can induce subperiosteal new bone formation in 
neonates (23). The clinical course of the hyperostotic episode was 
often protracted but resolved after about 2 years. By mid- to late 
childhood, the hyperostotic long bones in the affected children 
of families 2 and 3 had remodeled extensively. However, in each 
affected bone, the central portion of the diaphysis, correspond-
ing to the complete diaphysis of infancy, showed mild external 
and internal thickening of the cortex. In contrast, the diaphyseal 
and metaphyseal bone above and below the central region, which 
would have formed after the episode of hyperostosis, was radio-
graphically normal (data not shown). The epiphyses and growth 
plates were also radiographically normal.
In family 1, individuals with the R836C substitution (affected 
individuals and obligate carriers) had varying degrees of joint 
hyperlaxity that was first observed in early childhood (24). The 
hyperlaxity was apparent in large and small joints and allowed 
some individuals bearing the Caffey allele to voluntarily sublux 
Figure 2
Haplotype analyses of families with infantile cortical hyperostosis. (A) Family 1: Fine mapping of the locus for Caffey disease on chromosome 17q21. 
Standard techniques were used to establish the genetic locus of the disease in a large Canadian family with ADC (7, 8). Black symbols, affected 
individuals; white symbols with black dot in the center, obligate carriers; white symbols, unaffected individuals; gray symbols, deceased individuals. 
The unaffected individual II-9, who has unaffected children and grandchildren (data not shown), was only included to deduce the haplotypes of I-1 
and I-2 (indicated by italics); for LOD score calculations, his phenotype was entered as unknown. Marker D17S1795 provided a LOD score of 6.78 
(maximal theoretical LOD score, 7.12). Markers D17S1868 and D17S1877 (indicated in white on a black background) define the centromeric and 
telomeric boundary, respectively. The disease-associated haplotype is shown by black numbers on gray; markers consistent with a recombination 
are shown by white numbers on black. Uninformative data and haplotypes not associated with the disease are shown by black numbers on white. 
A C→T mutation at nucleotide 3040 of COL1A1 (see Figure 3) was identified by direct nucleotide sequence analysis only in affected members and 
obligate carriers. (B) Haplotypes of portions of the family shown in A and PCR-based confirmation of the identified mutation (see Methods). (C) 
Haplotypes and PCR analysis for family 2, comprising 2 affected brothers, their affected mother, and their healthy father. (D) Haplotypes and PCR 
analysis for family 3, comprising identical twin sisters affected by Caffey disease and their healthy parents and brother (19).
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their shoulders and finger joints (Figure 6). Instability of the 
joints, particularly the shoulder joints, worsened with age. These 
individuals had abnormally soft and hyperextensible skin, which 
was otherwise normal in appearance. They did not bruise easily. 
Members of family 1 who did not bear the Caffey allele did not 
have the skin or joint anomalies. The 3 members of family 2 with 
the R836C mutation (see Figure 2C) also had hyperextensible skin, 
joint hyperlaxity, and inguinal hernias, while the identical twins in 
family 3 did not demonstrate such anomalies.
None of the affected individuals or obligate carriers in any of 
the families had clinical signs of the major type I collagen disor-
der, osteogenesis imperfecta (25). In particular, they lacked gray-
blue sclerae, dentinogenesis imperfecta, premature hearing loss, 
short stature, deformities, and scoliosis (25, 26). Skull radiographs 
from the clinically affected identical twins did not contain worm-
ian bones, which can occur in patients with osteogenesis imper-
fecta (25, 26). Neither of the twins had radiographic evidence of 
platyspondyly, which is also a common feature of osteogenesis 
imperfecta. In family 1, 9 of the 18 individuals with Caffey disease, 
for whom detailed fracture histories were available, had a total of 
14 peripheral fractures (1–4 in each). Bone mineral density was 
assessed in 1 affected adult with Caffey disease from family 1 and 
the results were within normal limits for the lumbar spine and 
femoral neck; spinal radiographs in this patient showed no evi-
dence of platyspondyly or compression fractures.
Discussion
In family 1, we mapped ADC to an interval on chromosome 17q21. 
All affected individuals and obligate carriers were heterozygous for 
a 3040C→T transition in a CpG dinucleotide of exon 41 of COL1A1, 
which encodes the α1(I) chain of type I collagen. The same 3040C→T 
transition was also present in affected members of families 2 and 
3. The recurrent nature of the mutation indicates that the involved 
CpG dinucleotide is a mutational “hot spot” in COL1A1 (27–29). 
The mutation is predicted to introduce an R836C substitution 
into the triple-helical domain of α1(I) chains of type I collagen (22). 
Results from collagen biosynthetic studies supported this propos-
al, as cultured dermal fibroblasts from an affected individual pro-
duced an abnormal disulfide-bonded α1(I) dimer. Ultrastructural 
studies of the dermis revealed that in vivo, the mutation was associ-
ated with an abnormal collagen fibril architecture.
The absence of the nucleotide change in any of the databases of 
normal DNA sequence variants as well as in normal DNA samples 
supports our proposal that it is a cause of ADC. While the R836C 
mutation therefore appears to be required for the development of 
ADC, it remains uncertain how the identified amino acid change 
can result in a spatially and temporally limited increase in cortical 
bone formation. COL1A1 and COL1A2 mutations were not found 
in a sporadic case of Caffey disease in which, according to radio-
graphy, changes were limited to a single rib, which suggests that 
other genetic defects or environmental factors can lead to localized 
hyperostosis. Mutations of the type I collagen genes were also not 
detected in 2 cases of the prenatal form of the disease, which is 
usually more severe and may be inherited in an autosomal reces-
sive manner (21). Consequently, it is likely that the prenatal form 
of Caffey disease constitutes a separate disorder (11).
The R836C amino acid substitution changes the X posi-
tion of one of the 338 Gly-X-Y repeating amino acid triplets of 
the triple-helical domain of the α1(I) chain of type I collagen. 
Figure 3
Nucleotide sequence analysis of portions of exon 41 of COL1A1 and 
adjacent intronic regions of an affected individual from family 1. The 
individual was heterozygous for the transition, which is indicated by the 
arrow, and the approximate location of both primers for PCR amplifica-
tion is indicated by arrowheads within the schematic, partial drawing 
of COL1A1. Partial nucleotide sequence of wild-type and mutant (mut) 
exon 41 (capital letters), as well as adjacent intronic sequence (lower-
case letters), along with the encoded amino acid sequence, are shown. 
The 3040C→T transition (indicated by an asterisk), which alters the 
first nucleotide of the second-to-last codon in exon 41, is predicted to 
result in the substitution of an arginine (R) 836 to a cysteine (C) residue 
(R836C). The approximate location of the R836C mutation within the 
triple-helical region of the collagen fibril is schematically shown [bot-
tom: thin lines, α1(I) chains; thick line, α2(I) chain], as is the location of 
the R134C mutation previously described in 2 unrelated patients with 
Ehlers-Danlos syndrome type I (31).
Figure 4
Dermal ultrastructure from proband IV-2 of family 1. (A) Ultrastructure of 
the extracellular matrix of the proband’s dermis (magnification, ×60,000). 
The collagen fibrils are more variable in shape and size and are less 
densely packed than in control samples. The fibrils are also larger 
(Caffey disease, 108 ± 15 nm; control, 91 ± 8 nm; n = 1,000; P < 0.0001). 
Granular material is visible in the matrix surrounding the collagen fibrils. 
(B) Ultrastructure of control dermis. In contrast to the proband’s dermis, 
the collagen fibrils in the control dermis are round, uniform in size, tightly 
packed, and are not surrounded by granular material.
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Cysteine residues are normally present in the amino and carboxyl 
propeptides of type I procollagen chains, but they are removed 
when type I procollagen is enzymatically processed to type I col-
lagen (30). While many G→C mutations have been described in 
osteogenesis imperfecta, only 1 other R→C amino acid substitu-
tion has been reported in the α1(I) chain of type I collagen. Two 
unrelated patients with classical Ehlers-Danlos syndrome type 1 
were heterozygous for a 934C→T transition at a CpG dinucleo-
tide in exon 14 of COL1A1 (31). The resulting amino acid substi-
tution, R134C, also involved the X position of a Gly-X-Y triplet 
within the main triple-helical domain of the α1(I) chain of type I 
collagen (Figure 3). Ultrastructural studies of skin biopsies from 
these patients revealed variability in diameter and irregularity of 
dermal collagen fibrils, with granulofilamentous material visible 
along the collagen fibrils (similar to what is shown in Figure 4A), 
and collagen biosynthetic studies using fibroblast cultures bear-
ing the R134C substitution also showed disulfide-bonded α1(I) 
dimers within the fibroblasts. Thus, the ultrastructural and 
biosynthetic anomalies produced by the R134C and the R836C 
substitutions were similar. However, in contrast to the R134C 
substitution that was associated with a classical Ehlers-Danlos 
syndrome type I phenotype (soft, velvety, and hyperextensible 
skin; numerous atrophic paper scars of the skin; ecchymoses on 
the legs; and generalized joint hyperlaxity), the present R836C 
Figure 5
Collagen biosynthesis by cultured fibroblasts from proband IV-2 of fam-
ily 1. (A) One-dimensional gel electrophoresis of dermal and fibroblast 
collagens: lane 1, pepsin-solubilized collagen from normal dermis (ND); 
lane 2, proband fibroblast cell layer collagens; lane 3, proband medium 
collagens; lane 4, reduced proband fibroblast cell layer collagens; lane 5, 
reduced proband medium collagens; lane 6, control fibroblast cell layer 
collagens; lane 7, control medium collagens. All samples contained α1(I) 
and α2(I) monomeric chains of type I collagen. Control dermis (lane 1) 
contained α1(I) dimers (β11) and α1(I)/α2(I) dimers (β12) with lysine-
derived cross-linkages; these cross-linkages were partially blocked with 
the addition of β-aminopropionitrile in all fibroblast cultures. The unre-
duced dermal and fibroblast culture samples contained disulfide-bond-
ed type III collagen trimers [α1(III)3]. There was an additional protein 
band in the unreduced proband samples (arrowheads, lanes 2 and 3), 
designated β11′, which was more abundant in the cell layer than in the 
medium. This band migrated slightly slower than the dermal β11 dimer. 
The abnormal band disappeared, along with the type III collagen trimer, 
after reduction of disulfide bonds with DTT. (B) Two-dimensional gel 
electrophoresis of the proband’s fibroblast cell layer collagens. Disulfide 
bonds were unreduced in the first dimension and reduced with DTT in 
the second dimension. The abnormal protein band in A, lane 2, was 
dissociated by DTT into proteins, designated α1(I)′, which migrated in a 
similar manner to control α1(I) chains.
Figure 6
Voluntary subluxation of various joints in ADC patients. Photographs of 4 individuals carrying the R836C mutation (III-13, IV-2, IV-3, and IV-4 
of family 1): upper left, 2 individuals with subluxation of the shoulders; lower left, 2 views of patellar subluxation; right: views of hyperextension 
and subluxation in the fingers and the elbow.
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substitution was associated with episodes of infantile cortical 
hyperostosis, and 2 of the 3 Caffey families showed features of 
Ehlers-Danlos syndrome type III (24). Interestingly, neither R→C 
mutation was associated with osteogenesis imperfecta.
There are several possible mechanisms by which the R836C 
mutation could result in the observed ADC phenotype. The 
analysis of collagen fibrils in skin fibroblasts showed increased 
disulfide crosslinking, either within or between mutant collagen 
fibrils, which may be responsible for the observed alterations 
in collagen architecture. Disulfide crosslinking may also occur 
between the mutant collagens and other cystein-containing pro-
teins in the bone matrix. The Caffey mutation may furthermore 
disrupt an important site of interaction with other peptides or 
proteins. Arg836 is located within the carboxyterminal cyano-
gen bromide peptide 6 (CB6) of the α1(I) chain, which has been 
shown to bind with high affinity to IL-2 and to the amyloid pro-
tein precursor (APP) (32–34). However, the CB6 peptide compris-
es 218 amino acid residues, i.e. approximately 21% of the α1(I) 
chain (22), and the specific binding sites for IL-2 and APP within 
the CB6 peptide are currently unknown. It also is plausible that 
the R836C substitution within the α1(I) chain reduces the ther-
mal stability of the collagen triple helix. Based on studies with 
a host-guest collagen peptide, Ac-(Gly-Pro-Hyp)3-Gly-X-Y-(Gly-
Pro-Hyp)4-Gly-Gly-CONH2, in which an arginine residue had 
been replaced with a cysteine residue in the X position (30, 35), 
the R836C mutation identified in Caffey patients would be pre-
dicted to decrease the melting temperature of the collagen tri-
ple helix by 4.5°C. This change could provide another possible 
explanation for the observed alterations in collagen architec-
ture. Last, prostaglandins may be involved in the development 
of hyperostosis, as short-term PGE1 or PGE2 administration for 
the treatment of ductal-dependent cardiac lesions typically leads 
to bone changes that resemble those present in ADC (12–14, 36). 
The inflammatory signs that often accompany the hyperostot-
ic lesions in Caffey disease support this hypothesis. However, 
examination of additional ADC families, as well as in vitro and 
in vivo studies, are needed to help define the mechanism(s) that 
lead to the disease phenotype.
While the hyperostotic lesions in ADC occur only in infancy, 
the mutant α1(I) chain is presumably present in the bone matrix 
throughout life. Based on our radiographic observations, detach-
ment of the periosteum from the underlying bone appears to be 
a key pathological process in the onset of episodes of cortical 
hyperostosis. However, there was no consistent reporting of 
events in our families that may have precipitated this periosteal 
detachment. The only recurrent finding was the onset of episodes 
of cortical hyperostosis within the first 5 months of postnatal 
life, which suggests that infants in this age group may have an 
increased susceptibility to periosteal injury. Consistent with this 
hypothesis, a radiographic study of babies who died of sudden 
infant death syndrome between 1 and 4 months of age showed 
that mild subperiosteal new bone formation, which was distinct 
from the underlying diaphysis and metaphysis, had occurred 
in the long bones of 35% of the cases (37). Furthermore, large 
amounts of subperiosteal new bone characteristically accompany 
healing fractures (38), osteomyelitis (39), and scurvy (40, 41) in 
neonates and infants. In all of these conditions, the bone can 
enlarge in diameter by several fold but remodels over the follow-
ing 2 years, similar to what occurs with the hyperostotic lesions 
in Caffey disease. In contrast, subperiosteal elevation is more lim-
ited in older children with fractures and osteomyelitis (42). Thus, 
intrinsic differences in periosteal bone formation in infants and 
adults may explain the absence of hyperostotic lesions in adults 
with the R836C mutation. Furthermore, differences in the clini-
cal threshold for periosteal detachment, influenced by the genet-
ic background and/or environmental exposures, may explain the 
incomplete penetrance of the hyperostotic phenotype. Similar 
explanations have been provided to account for the widely dif-
fering fracture rates among affected individuals in families with 
classical osteogenesis imperfecta type I due to autosomal domi-
nant COL1A1 haploinsufficiency (26, 43, 44).
Our clinical evaluations of the affected individuals in the 3 fami-
lies have extended the reported phenotype of Caffey disease (1). 
Individuals bearing the Caffey allele in 2 of the 3 families had fea-
tures that were similar to those observed in patients with Ehlers-
Danlos syndrome type III (24), and the absence of such features 
in the third family may be attributed to the current young age of 
the affected individuals. The relatively high number of fractures in 
family 1 suggested that bone fragility may also be part of the phe-
notype. However, bone densitometry studies in an affected adult 
patient (IV-2) were found to be normal, and similar fracture rates 
can occur in the normal population (45). Nonetheless, bone health 
of the ADC families requires further study, as radiographs taken 
during the episodes of cortical hyperostosis show that abnormali-
ties in cortical and endosteal bone accompany the more obvious 
formation of subperiosteal new bone.
In summary, ADC is associated with a mutation in COL1A1 and 
thus belongs to the family of type I collagen–related conditions 
that include osteogenesis imperfecta types I–IV (46); Ehlers-Dan-
los syndrome types I (31) and VII (47, 48) and a recessive cardiac 
valvular form (49); idiopathic osteoporosis (50); arterial dissec-
tions (51); and dermatofibrosarcoma protuberans, which was 
found to be associated with translocations between chromosomes 
17 and 22 leading to the production of a fusion protein consisting 
of α1(I) collagen and PDGF-β (52). The findings in the present 
study extend the phenotypic spectrum of disorders associated with 
genetic changes in the type I collagen genes to include a hyperos-
totic disorder, but it remains uncertain how the R836C mutation 
results in a temporally and spatially limited defect in bone.
Methods
Families with ADC. A large, 3-generation Canadian ADC family (family 1) 
was ascertained, and historical details concerning episodes of infantile cor-
tical hyperostosis were obtained from family members. Previous reports 
on this family also included detailed accounts of all episodes of possible 
infantile cortical hyperostosis (7, 8). These sources of information were 
combined in order to validate disease assignments within the pedigree. For 
the purposes of genetic linkage analysis, individuals in this family were 
designated as affected if they had radiographically proven Caffey disease 
(affected members) or if they had children diagnosed with Caffey disease 
(obligate carriers). Genomic DNA from 24 such individuals was available 
for study. Unrelated spouses were designated as unaffected.
Besides family 1, two additional small kindreds (families 2 and 3) were 
ascertained, which had 3 and 2 affected members, respectively. The small 
Canadian kindred (family 2) included the mother and her 2 children (see 
Figure 2C), who were clinically and radiographically affected by Caffey dis-
ease (see Figure 1), while the small Australian family (family 3) consisted 
of affected monozygotic twins, a healthy brother, and healthy parents (see 
Figure 2D) (19). A single sporadic case had hyperostosis of a rib, which was 
possibly due to ADC. Furthermore, 2 sporadic cases of the more severe 
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prenatal form of Caffey disease were studied (20, 21). Autosomal recessive 
inheritance was postulated for the prenatal cases (21).
Detailed information was obtained from all families concerning possible 
events that may have precipitated episodes of infantile cortical hyperosto-
sis. These enquiries were undertaken soon after the onset of the episodes 
of cortical hyperostosis in the affected children in families 2 and 3 as well 
as in some of the recently born affected members of the large family 1. The 
long-term sequelae of the condition in clinically affected individuals and in 
obligate carriers were determined. The long-term clinical features of the indi-
viduals in each family that did not bear the Caffey allele were also recorded.
Genetic screening and DNA analysis. In family 1, we performed a genome-wide 
scan with microsatellite markers spaced at about 10-centimorgan intervals 
(Webber set 9; Invitrogen Corp.) followed by fine mapping using commer-
cially available markers for the linked interval. We performed LOD score 
calculations using the Mlink program (http://linkage.rockefeller.edu/) 
assuming a disease frequency of 0.1%, equal allele frequencies, and 
autosomal dominant inheritance with full penetrance. Candidate genes 
in the linked region were identified and sequenced by the Massachusetts 
General Hospital Sequencing Core using Applied Biosystems Taq DyeDe-
oxy Terminator cycle sequencing kits and methods.
Once the putative Caffey gene and its mutation were identified, we 
screened genomic DNA from affected individuals and obligate carriers of 
the various families, as well as the sporadic cases and controls, by restric-
tion mapping of PCR products. For these studies, we used the forward 
primer AGCAGGGGAATATGGGTCAG and the reverse primer GGCCCT-
GAGAAAAACCATC to generate a 495-bp PCR product. The mutant PCR 
product lacked 1 of the cleavage sites for the restriction endonuclease 
HpyCH4IV, which thus allowed detection of the mutation by agarose gel 
electrophoresis after enzymatic digestion of the amplified DNA (wild-
type, bands of 259, 60, and 176 bp; mutant, bands of 319 and 176 bp; note 
that the 60-bp band is not shown in Figure 2B). In individuals who did 
not bear the R836C mutation in COL1A1, mutations were sought in other 
parts of COL1A1 as well as in COL1A2, as described previously (53).
Informed consent was obtained from all study participants prior to their 
inclusion in these studies. These studies have been approved by the institu-
tional review boards at the respective institutions and were performed in 
accordance with the guidelines of the Declaration of Helsinki.
Dermal histology and fibroblast cultures. Skin biopsies were obtained 
from the proband (IV-2) of family 1. We processed 1 biopsy for elec-
tron microscopy using previously described methods (54). The same 
methods were used to process the patient and control samples for elec-
tron microscopy. The second biopsy specimen was used to establish 
fibroblast cultures, which were grown to confluency in the presence 
of β-aminopropionitrile, which blocks the formation of lysine-derived 
cross-linkages, and ascorbate, which is required for normal prolyl- and 
lysyl-hydroxylation of collagen. The cultures were analyzed 5–7 days 
after plating, as previously described (55, 56). Fibroblast cultures from 
an age- and sex-matched individuals served as controls. Cell layer and 
medium fractions were analyzed separately, and the procollagens were 
converted to collagen by limited pepsin digestion. The collagens were 
resolved by 1-dimensional and 2-dimensional SDS-PAGE and stained 
with Coomassie G-250 (Invitrogen Corp.) (28). Where applicable, disul-
fide bonds were reduced with DTT.
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